Cargando…
Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori
Vonoprazan (VPZ) inhibits gastric acid secretion more potently than proton pump inhibitors. Recently, attention has been focused on the dual therapy with VPZ and amoxicillin (AMOX) for the eradication of H. pylori. The dual VPZ/AMOX therapy attains the sufficient eradication rate with lowering the r...
Autores principales: | Furuta, Takahisa, Yamade, Mihoko, Higuchi, Tomohiro, Takahashi, Satoru, Ishida, Natsuki, Tani, Shinya, Tamura, Satoshi, Iwaizumi, Moriya, Hamaya, Yasushi, Osawa, Satoshi, Sugimoto, Ken |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179648/ https://www.ncbi.nlm.nih.gov/pubmed/37176551 http://dx.doi.org/10.3390/jcm12093110 |
Ejemplares similares
-
C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis
por: Ishida, Natsuki, et al.
Publicado: (2021) -
Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis
por: Ishida, Natsuki, et al.
Publicado: (2021) -
Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome
por: Ishida, Natsuki, et al.
Publicado: (2021) -
Comparison between Prostaglandin E-major urinary metabolite and C-reactive protein levels to reflect endoscopic scores in patients with ulcerative colitis
por: Ishida, Natsuki, et al.
Publicado: (2021) -
Serum N-terminal telopeptide of type I collagen as a biomarker for predicting bone density loss in patients with Crohn disease
por: Ishida, Natsuki, et al.
Publicado: (2021)